Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients

This study has been completed.
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
First received: September 2, 2008
Last updated: NA
Last verified: September 2008
History: No changes posted
Fenofibrate increases adiponectin levels, but reduces leptin levels

Condition Intervention Phase
Drug: fenofibrate
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Gachon University Gil Medical Center:

Study Start Date: January 2005
Study Completion Date: August 2008
Arms Assigned Interventions
Experimental: fenofibrate 160 mg, placebo Drug: fenofibrate


Ages Eligible for Study:   25 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hypertriglyceridemia

Exclusion Criteria:

  • chronic liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00745407

Korea, Republic of
Gil Medical Center
Incheon, Korea, Republic of, 405760
Sponsors and Collaborators
Gachon University Gil Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00745407     History of Changes
Other Study ID Numbers: GMC 200511 
Study First Received: September 2, 2008
Last Updated: September 2, 2008
Health Authority: South Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:
insulin sensitivity
hypertriglyceridemic patients

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on April 27, 2016